Home > Resources > Whitepapers > Biotechnology An agent for sustainable socio-economic transformation

Biotechnology An agent for sustainable socio-economic transformation

February 5, 2016

One of the key government departments of India credited with heralding the era of adventure and entrepreneurship in the country’s science – the Department of Biotechnology (DBT) – is entering its youthful years. Thirty, as they say, is the new twenty. In these three eventful decades, DBT’s achievements have been many, in terms of the science it has enabled, the policies it has introduced, as well as the linkages it has established across disciplines and countries. DBT’s many forays into biological sciences education and its societal contributions have also bolstered its position as a formidable science-faring body in the country – as a confident young global icon who looks to the future, armed with a dynamic policy framework, the spirit of adventure and ample room for self-criticism.

Spotlight

MedImmune

As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

OTHER WHITEPAPERS

Long-term follow-up studies of cell and gene therapies

whitePaper | September 29, 2022

The market is experiencing a surge in the availability of cell and gene therapies (CGTs); it’s estimated that by 2025 as many as 20 will be introduced into the US each year.1,2

Lipid Nanoparticle and Liposome

whitePaper | September 12, 2022

Lipid nanoparticles (LNPs) and liposomes are variations of lipid-based drug carriers differing in their internal structure.

BIOPHARMACEUTICAL INDUSTRY AND INTERRELATED BIOTECHNOLOGY ORGANIZATIONS

whitePaper | November 21, 2019

Our Accounting and Finance team has published an overview of the accounting and finance challenges facing the Biopharmaceutical industry and interrelated Biotechnology organizations.

Becoming a life sciences superpower

whitePaper | September 1, 2021

This report advocates for increased, long-term public investment in research and innovation, particularly in the life sciences sector, to accelerate the UK on its trajectory as a global leader in the field. This report sets out recommendations ahead of the Comprehensive Spending Review for policymakers to support innovative businesses, achieve the Prime Minister’s aim of becoming a life sciences superpower, and ultimately, deliver health benefits for Britain – and the world – for generations to come.

Recruitment, Retention & Diversity: The Evolution of Patient Engagement in Clinical Trials

whitePaper | January 23, 2023

Recruitment, retention, and diversity are critical elements of clinical trials that, if insufficient, can jeopardize successful trial completion.

Osmolality monitoring for UF/DF and CEXcapture of mAbs from mammalian cell cultures

whitePaper | July 25, 2022

The goal of each process step is to facilitate the production of a consistent product with high yield, quality, purity, and functionality. Throughout each step various Process Analytical Tools (PAT) are used to ensure quality and production metrics are maintained.